This is also supported by prior work showing upregulation of type I IFN in a PDX model of Brca2 WT triple-negative breast cancer at higher olaparib doses than in a BRCA1-mutated PDX model [52]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.